GlassScriptPhysician profile
Mackenzie Taylor
NPI 1194281931
$10,238.24
in general payments reported to CMS, 2019-2025
27 companies · $14.39 in 2025
The $14.39 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,804 · 2022: $3,961 · 2023: $382 · 2024: $76.03 · 2025: $14.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $206.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,681.96 | 2021-2025 | |
| Allergan, INC. | $831.09 | 2021-2022 | |
| Horizon Therapeutics Plc | $342.45 | 2022-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $200.11 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $130.63 | 2021 | |
| Octapharma USA, INC. | $122.38 | 2022-2024 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $91.20 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $69.92 | 2021-2022 | |
| Ucb, INC. | $64.95 | 2021-2022 | |
| Genzyme Corporation | $59.40 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $57.08 | 2021 | |
| Sk Life Science, INC. | $53.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $45.15 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $42.51 | 2021 | |
| Lilly USA, LLC | $31.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $31.77 | 2021-2022 | |
| Tanabe Pharma America, INC. | $29.10 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $28.34 | 2021-2022 | |
| Argenx US, INC. | $24.35 | 2022 | |
| Grifols USA, LLC | $23.76 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $22.40 | 2022 | |
| Baxter Healthcare | $21.90 | 2022 | |
| Neurelis, INC. | $19.13 | 2021 | |
| Ge Healthcare | $14.07 | 2021 | |
| Kls-Martin L.P. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.